FDA Approves Cetraxal Otic Solution
FDA Approves Cetraxal Otic Solution
May 1, 2009 - The United States Food and Drug Administation has approved Cetraxal (ciprofloxacin otic solution) 0.2% for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aerugenosa or Staphylococcus aureus. More information expected to be available soon.Posted: May 2009
Related articles
- Salvat Announces Submission of Complete Response to FDA Approvable Letter for Cetraxal - November 6, 2008
- Salvat Announces the FDA Acceptance of NDA for its Cetraxal Otic Solution - September 14, 2005
- SALVAT Files NDA for its Cetraxal Otic - Ciprofloxacin Otic- 0.2% Solution, for the Treatment of External Otitis - June 10, 2005
- Salvat Seeks FDA Approval for its Cetraxal Otic (Ciprofloxacin Otic) 0.2% Solution, for the Treatment of External Otitis - April 18, 2005
Cetraxal (ciprofloxacin otic) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
